The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases and hemophilia.
Looking for leads, investment insights, or competitive intelligence?
News about Biogen
Novartis and Amgen want to find out with an experimental drug.
AbbVie and Alector hope to apply immunotherapy to dementia and Alzheimer's.
U.S.-based firms made up a fifth of those in a 2017 "A list."
Goldman analysts think the drug could eventually ring in $12 billion in sales if approved.